{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:04:41Z","timestamp":1794449081515,"version":"4.9.1"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02639-0","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:32:11Z","timestamp":1774247531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multifunctional chitosan\u2013doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Gaurav","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muskan","family":"Leharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humood","family":"Al Shmrany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh Kumar","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2639_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010.","journal-title":"Breast"},{"key":"2639_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/CAAC.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/CAAC.21834.","journal-title":"CA Cancer J Clin"},{"key":"2639_CR3","doi-asserted-by":"publisher","first-page":"107283","DOI":"10.1016\/j.jddst.2025.107283","volume":"112","author":"KA Khan","year":"2025","unstructured":"Khan KA, Chandra J, Gupta G, Ghazwani M, Hani U, Kesharwani P. Mannose directed nanoparticle delivery systems enhancing targeted cancer treatment. J Drug Deliv Sci Technol. 2025;112:107283. https:\/\/doi.org\/10.1016\/j.jddst.2025.107283.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR4","doi-asserted-by":"publisher","unstructured":"O Freihat O, Sipos D, Kovacs A. Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data, Front Public Health. 2025;13. https:\/\/doi.org\/10.3389\/fpubh.2025.1622954.","DOI":"10.3389\/fpubh.2025.1622954"},{"key":"2639_CR5","doi-asserted-by":"publisher","unstructured":"Chauhan M, Almoyad MAA, Wahab S, Goh KW, Gupta G, Sahebkar A, Kesharwani P. Exploring the efficacy and mechanisms of exemestane-loaded nanoparticles in targeted breast cancer therapy. Biomater Adv. 2026;179. https:\/\/doi.org\/10.1016\/j.bioadv.2025.214519.","DOI":"10.1016\/j.bioadv.2025.214519"},{"key":"2639_CR6","doi-asserted-by":"publisher","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge, Cells. 2019;8. https:\/\/doi.org\/10.3390\/cells8090957.","DOI":"10.3390\/cells8090957"},{"key":"2639_CR7","doi-asserted-by":"publisher","unstructured":"Kesharwani P, Halwai K, Jha SK, Al Mughram MH, Almujri SS, Almalki WH, Sahebkar A. Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers. Mol Cancer. 2024;23. https:\/\/doi.org\/10.1186\/s12943-024-02163-z.","DOI":"10.1186\/s12943-024-02163-z"},{"key":"2639_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells12040659","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Ko\u0142at D, Ka\u0142uzi\u0144ska-Ko\u0142at \u017b, Celik I, et al. Doxorubicin\u2014an agent with multiple mechanisms of anticancer activity. Cells. 2023;12:659. https:\/\/doi.org\/10.3390\/cells12040659.","journal-title":"Cells"},{"key":"2639_CR9","doi-asserted-by":"publisher","unstructured":"Wang LC, Wang LS, Li AX, Shi ZZ, Li YQ, Huang W, Chen SM, Han F, Zhu DQ. Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer. Technol Cancer Res Treat. 2020;19. https:\/\/doi.org\/10.1177\/1533033820928435.","DOI":"10.1177\/1533033820928435"},{"key":"2639_CR10","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1021\/ACS.MOLPHARMACEUT.5B00827","volume":"12","author":"MW Amjad","year":"2015","unstructured":"Amjad MW, Amin MCIM, Katas H, Butt AM, Kesharwani P, Iyer AK. In vivo antitumor activity of folate-conjugated cholic acid-polyethylenimine micelles for the codelivery of doxorubicin and siRNA to colorectal adenocarcinomas. Mol Pharm. 2015;12:4247\u201358. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.5B00827.","journal-title":"Mol Pharm"},{"key":"2639_CR11","doi-asserted-by":"publisher","unstructured":"Ajith AK, Subramani S, Manickam AH, Ramasamy S. Chemotherapeutic Resistance Genes of Breast Cancer Patients \u2013 An Overview. Adv Pharm Bull. 2021. https:\/\/doi.org\/10.34172\/apb.2022.048.","DOI":"10.34172\/apb.2022.048"},{"key":"2639_CR12","doi-asserted-by":"publisher","unstructured":"Raies S, Rehman U, Siddiqua A, Wahab S, Gupta G, Goh KW, Kesharwani P. Silver nanoparticles: Forging a new frontline in lung cancer therapy. Biomater Adv. 2025; 177. https:\/\/doi.org\/10.1016\/j.bioadv.2025.214395.","DOI":"10.1016\/j.bioadv.2025.214395"},{"key":"2639_CR13","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3390\/cancers17142303","volume":"17","author":"A Bhadran","year":"2025","unstructured":"Bhadran A, Polara H, Babanyinah GK, Baburaj S, Stefan MC. Advances in doxorubicin chemotherapy: emerging polymeric nanocarriers for drug loading and delivery. Cancers (Basel). 2025;17:2303. https:\/\/doi.org\/10.3390\/cancers17142303.","journal-title":"Cancers (Basel)"},{"key":"2639_CR14","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.7150\/thno.38069","volume":"10","author":"P Mi","year":"2020","unstructured":"Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10:4557\u201388. https:\/\/doi.org\/10.7150\/thno.38069.","journal-title":"Theranostics"},{"key":"2639_CR15","doi-asserted-by":"publisher","first-page":"137708","DOI":"10.1016\/j.ijbiomac.2024.137708","volume":"284","author":"X Bian","year":"2025","unstructured":"Bian X, Yu X, Lu S, Jia L, Li P, Yin J, et al. Chitosan-based nanoarchitectures for siRNA delivery in cancer therapy: a review of pre-clinical and clinical importance. Int J Biol Macromol. 2025;284:137708. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.137708.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR16","doi-asserted-by":"publisher","unstructured":"Jahan A, Vadi A, Rehman U, Orayj K, Mohammad AAS, Gupta G, Goh KW, Kesharwani P. RNA-encapsulated lipid nanoparticles for breast cancer therapy: Advances, challenges, and translational perspectives. J Drug Deliv Sci Technol. 2026;115. https:\/\/doi.org\/10.1016\/j.jddst.2025.107834.","DOI":"10.1016\/j.jddst.2025.107834"},{"key":"2639_CR17","doi-asserted-by":"publisher","first-page":"145537","DOI":"10.1016\/j.ijbiomac.2025.145537","volume":"319","author":"SS Deshmukh","year":"2025","unstructured":"Deshmukh SS, Nijhawan HP, Yadav KS. Chitosan-based copolymeric nanocarrier systems: a novel paradigm for targeted breast cancer therapy. Int J Biol Macromol. 2025;319:145537. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145537.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR18","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/J.NTM.2024.100040","volume":"3","author":"AK Grewal","year":"2024","unstructured":"Grewal AK, Salar RK. Chitosan nanoparticle delivery systems: an effective approach to enhancing efficacy and safety of anticancer drugs. Nano TransMed. 2024;3:100040. https:\/\/doi.org\/10.1016\/J.NTM.2024.100040.","journal-title":"Nano TransMed"},{"key":"2639_CR19","doi-asserted-by":"publisher","unstructured":"Carlino F, Solinas C, Orditura M, Bisceglia MD, Pellegrino B, Diana A. Editorial: Heterogeneity in breast cancer: clinical and therapeutic implications. Front Oncol. 2024;14. https:\/\/doi.org\/10.3389\/fonc.2024.1321654.","DOI":"10.3389\/fonc.2024.1321654"},{"key":"2639_CR20","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1038\/s41598-025-88394-6","volume":"15","author":"ME Lacruz","year":"2025","unstructured":"Lacruz ME, Thies S, Schmidt-Pokrzywniak A, Wittenberg I, Engler T, Reinwald F, et al. Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer. Sci Rep. 2025;15:4584. https:\/\/doi.org\/10.1038\/s41598-025-88394-6.","journal-title":"Sci Rep"},{"key":"2639_CR21","doi-asserted-by":"publisher","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A. Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014An updated review. Cancers (Basel). 2021; 13. https:\/\/doi.org\/10.3390\/cancers13174287.","DOI":"10.3390\/cancers13174287"},{"key":"2639_CR22","doi-asserted-by":"publisher","unstructured":"Cortiana V, Kannan S, Vallabhaneni H, Gambill J, Nadar S, Jigar Kumar Rangrej V, Park CH, Leyfman Y. Early and hereditary breast cancer: advances in risk stratification and imaging approaches. Ther Adv Med Oncol. 2025;17. https:\/\/doi.org\/10.1177\/17588359251349677.","DOI":"10.1177\/17588359251349677"},{"key":"2639_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/br.2013.187","volume":"2","author":"MH Zhang","year":"2014","unstructured":"Zhang MH, Man HT, Zhao XD, Dong N, Ma SL. Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomed Rep. 2014;2:41\u201352. https:\/\/doi.org\/10.3892\/br.2013.187.","journal-title":"Biomed Rep"},{"key":"2639_CR24","doi-asserted-by":"publisher","unstructured":"Kim N, Lukong KE. Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action. Oncol Rev. 2025;19. https:\/\/doi.org\/10.3389\/or.2025.1564642.","DOI":"10.3389\/or.2025.1564642"},{"key":"2639_CR25","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3390\/medicina61071280","volume":"61","author":"OM Burciu","year":"2025","unstructured":"Burciu OM, Merce A-G, Cerbu S, Iancu A, Popoiu T-A, Cobec IM, et al. Current endocrine therapy in hormone-receptor-positive breast cancer: from tumor biology to the rationale for therapeutic tunning. Medicina (B Aires). 2025;61:1280. https:\/\/doi.org\/10.3390\/medicina61071280.","journal-title":"Medicina (B Aires)"},{"key":"2639_CR26","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","volume":"212","author":"AM Karim","year":"2023","unstructured":"Karim AM, Kwon JE, Ali T, Jang J, Ullah I, Lee Y-G, et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol. 2023;212:115545. https:\/\/doi.org\/10.1016\/j.bcp.2023.115545.","journal-title":"Biochem Pharmacol"},{"key":"2639_CR27","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.3390\/curroncol30080545","volume":"30","author":"S Lavasani","year":"2023","unstructured":"Lavasani S, Healy E, Kansal K. Locoregional treatment for early-stage breast cancer: current status and future perspectives. Curr Oncol. 2023;30:7520\u201331. https:\/\/doi.org\/10.3390\/curroncol30080545.","journal-title":"Curr Oncol"},{"key":"2639_CR28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s12672-025-02233-8","volume":"16","author":"M Aghebati","year":"2025","unstructured":"Aghebati M, Hossieni R, Makeh AS, Shirzadi A, Akbari ME. Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients. Discov Oncol. 2025;16:970. https:\/\/doi.org\/10.1007\/s12672-025-02233-8.","journal-title":"Discov Oncol"},{"key":"2639_CR29","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10:1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes Dis"},{"key":"2639_CR30","doi-asserted-by":"publisher","unstructured":"Bhutani V, Varzideh F, Wilson S, Kansakar U, Jankauskas SS, Santulli G. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update. J Cardiovasc Dev Dis. 2025;12. https:\/\/doi.org\/10.3390\/jcdd12060207.","DOI":"10.3390\/jcdd12060207"},{"key":"2639_CR31","doi-asserted-by":"publisher","unstructured":"Desai N, Sahel D, Kubal B, Postwala H, Shah Y, Chavda VP, Fernandes C, Khatri DK, Vora LK. Role of the Extracellular Matrix in Cancer: Insights into Tumor Progression and Therapy. Adv Ther. 2025;8. https:\/\/doi.org\/10.1002\/adtp.202400370.","DOI":"10.1002\/adtp.202400370"},{"key":"2639_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.20517\/cdr.2021.19","volume":"4","author":"J Goebel","year":"2021","unstructured":"Goebel J, Chmielewski J, Hrycyna CA. The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors. Cancer Drug Resist. 2021;4:784\u2013804. https:\/\/doi.org\/10.20517\/cdr.2021.19.","journal-title":"Cancer Drug Resist"},{"key":"2639_CR33","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.7150\/ijms.111217","volume":"22","author":"AS Alhamed","year":"2025","unstructured":"Alhamed AS, El-Wetidy MS, Abdelwahed MM, Attia SM, Alabkka AM, Alaraj SA, et al. Modulation of chemotherapy sensitivity of breast cancer cells through transforming growth factor-beta pathway-mediated alterations in DNA damage response. Int J Med Sci. 2025;22:2031\u20139. https:\/\/doi.org\/10.7150\/ijms.111217.","journal-title":"Int J Med Sci"},{"key":"2639_CR34","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.21037\/tcr-24-1129","volume":"13","author":"R Chen","year":"2024","unstructured":"Chen R, Yu Y, Liu R, Chen Q. Targeting breast cancer resistance protein (BCRP\/ABCG2) in cancer. Transl Cancer Res. 2024;13:6550\u201364. https:\/\/doi.org\/10.21037\/tcr-24-1129.","journal-title":"Transl Cancer Res"},{"key":"2639_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5455\/jabet.2026.01","volume":"9","author":"S Nath","year":"2026","unstructured":"Nath S, Akash M, Tanim M, Akhteruzzaman S, Mostafa M, Sajib A. Multidrug transporters P-GP, MRP1, and ABCG2 in chemoresistant breast and colorectal cancer cells\u2014who takes the lead? J Adv Biotechnol Exp Ther. 2026;9:1. https:\/\/doi.org\/10.5455\/jabet.2026.01.","journal-title":"J Adv Biotechnol Exp Ther"},{"key":"2639_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s11671-025-04308-5","volume":"20","author":"NR Ramayanam","year":"2025","unstructured":"Ramayanam NR, Bukke SPN, Moka MK, Dehingia H, Bordoloi A, Debbarma R, et al. Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer. Discov Nano. 2025;20:111. https:\/\/doi.org\/10.1186\/s11671-025-04308-5.","journal-title":"Discov Nano"},{"key":"2639_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/gcc.22921","volume":"60","author":"RMM Ali","year":"2021","unstructured":"Ali RMM, McIntosh SA, Savage KI. Homologous recombination deficiency in breast cancer: implications for risk, cancer development, and therapy. Genes Chromosom Cancer. 2021;60:358\u201372. https:\/\/doi.org\/10.1002\/gcc.22921.","journal-title":"Genes Chromosom Cancer"},{"key":"2639_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13073-025-01488-8","volume":"17","author":"K Nesic","year":"2025","unstructured":"Nesic K, Parker P, Swisher EM, Krais JJ. DNA repair and the contribution to chemotherapy resistance. Genome Med. 2025;17:62. https:\/\/doi.org\/10.1186\/s13073-025-01488-8.","journal-title":"Genome Med"},{"key":"2639_CR39","doi-asserted-by":"publisher","unstructured":"LiuY, Wang M, Liu W, Jing J, Ma H. Olaparib and Doxorubicin Co-Loaded Polypeptide Nanogel for Enhanced Breast Cancer Therapy. Front Bioeng Biotechnol. 2022;10. https:\/\/doi.org\/10.3389\/fbioe.2022.904344.","DOI":"10.3389\/fbioe.2022.904344"},{"key":"2639_CR40","doi-asserted-by":"publisher","unstructured":"Yang Y, Zhao Q, Peng Z, Zhou Y, Niu MM, Chen L. A GSH\/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy. Front Pharmacol. 2022;12. https:\/\/doi.org\/10.3389\/fphar.2021.811724.","DOI":"10.3389\/fphar.2021.811724"},{"key":"2639_CR41","doi-asserted-by":"publisher","unstructured":"Zhao N, Woodle MC, Mixson AJ. Advances in Delivery Systems for Doxorubicin. J Nanomed Nanotechnol. 2018;09. https:\/\/doi.org\/10.4172\/2157-7439.1000519.","DOI":"10.4172\/2157-7439.1000519"},{"key":"2639_CR42","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.21037\/tcr.2020.01.53","volume":"9","author":"J Chen","year":"2020","unstructured":"Chen J, Liu S, Su Y, Zhang X. ALDH1+ stem cells demonstrate more stem cell-like characteristics than CD44+\/CD24\u2013\/low stem cells in different molecular subtypes of breast cancer. Transl Cancer Res. 2020;9:1652\u20139. https:\/\/doi.org\/10.21037\/tcr.2020.01.53.","journal-title":"Transl Cancer Res"},{"key":"2639_CR43","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1158\/1078-0432.CCR-08-1479","volume":"15","author":"T Tanei","year":"2009","unstructured":"Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers. Clin Cancer Res. 2009;15:4234\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1479.","journal-title":"Clin Cancer Res"},{"key":"2639_CR44","doi-asserted-by":"publisher","unstructured":"Yu T, Li Y, Gu X, Li Q. Development of a Hyaluronic Acid-Based Nanocarrier Incorporating Doxorubicin and Cisplatin as a pH-Sensitive and CD44-Targeted Anti-Breast Cancer Drug Delivery System. Front Pharmacol. 2020;11. https:\/\/doi.org\/10.3389\/fphar.2020.532457.","DOI":"10.3389\/fphar.2020.532457"},{"key":"2639_CR45","doi-asserted-by":"publisher","first-page":"e12594","DOI":"10.7717\/peerj.12594","volume":"10","author":"VO Poku","year":"2022","unstructured":"Poku VO, Iram SH. A critical review on modulators of multidrug resistance protein 1 in cancer cells. PeerJ. 2022;10:e12594. https:\/\/doi.org\/10.7717\/peerj.12594.","journal-title":"PeerJ"},{"key":"2639_CR46","doi-asserted-by":"publisher","unstructured":"Yang S, Fang Y, Ma Y, Wang F, Wang Y, Jia J, Yang Y, Sun W, Zhou Q, Li Z. Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice. Clin Transl Med. 2025;15. https:\/\/doi.org\/10.1002\/ctm2.70313.","DOI":"10.1002\/ctm2.70313"},{"key":"2639_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.61186\/ibj.4960","volume":"29","author":"P Tarighi","year":"2025","unstructured":"Tarighi P, Mousavi Esfahani SM, Emamjomeh A, Mirjalili SZ, Mirzabeigi P. Optimizing cancer treatment: a comprehensive review of active and passive drug delivery strategies. Iran Biomed J. 2025;29:173\u201388. https:\/\/doi.org\/10.61186\/ibj.4960.","journal-title":"Iran Biomed J"},{"key":"2639_CR48","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.2147\/DDDT.S367586","volume":"16","author":"MM Habibullah","year":"2022","unstructured":"Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, et al. Human growth hormone fragment 176\u2013191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug Des Devel Ther. 2022;16:1963\u201374. https:\/\/doi.org\/10.2147\/DDDT.S367586.","journal-title":"Drug Des Devel Ther"},{"key":"2639_CR49","doi-asserted-by":"publisher","unstructured":"Van Ravenstein SX, Mehta KP, Kavlashvili T, Byl JAW, Zhao R, Osheroff N, Cortez D, Dewar JM. Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms. EMBO J. 2022;41. https:\/\/doi.org\/10.15252\/embj.2022110632.","DOI":"10.15252\/embj.2022110632"},{"key":"2639_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11864-018-0547-8","volume":"19","author":"S Jasra","year":"2018","unstructured":"Jasra S, Anampa J. Anthracycline use for early stage breast cancer in the modern era: a review. Curr Treat Options Oncol. 2018;19:30. https:\/\/doi.org\/10.1007\/s11864-018-0547-8.","journal-title":"Curr Treat Options Oncol"},{"key":"2639_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.breast.2022.06.007","volume":"65","author":"AT Vuger","year":"2022","unstructured":"Vuger AT, Tiscoski K, Apolinario T, Cardoso F. Anthracyclines in the treatment of early breast cancer friend or foe? Breast. 2022;65:67\u201376. https:\/\/doi.org\/10.1016\/j.breast.2022.06.007.","journal-title":"Breast"},{"key":"2639_CR52","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s13346-024-01648-0","volume":"15","author":"A Bisht","year":"2025","unstructured":"Bisht A, Avinash D, Sahu KK, Patel P, Das Gupta G, Das Kurmi B. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Deliv Transl Res. 2025;15:102\u201333. https:\/\/doi.org\/10.1007\/s13346-024-01648-0.","journal-title":"Drug Deliv Transl Res"},{"key":"2639_CR53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1634\/theoncologist.2017-0672","volume":"23","author":"AN Shah","year":"2018","unstructured":"Shah AN, Gradishar WJ. Adjuvant anthracyclines in breast cancer: what is their role? Oncologist. 2018;23:1153\u201361. https:\/\/doi.org\/10.1634\/theoncologist.2017-0672.","journal-title":"Oncologist"},{"key":"2639_CR54","doi-asserted-by":"publisher","first-page":"839","DOI":"10.18295\/2075-0528.2891","volume":"25","author":"HA Al-Lawati","year":"2025","unstructured":"Al-Lawati HA, Al Baimani K, Al Rawahi MN. Anthracycline-induced cardiomyopathy in breast cancer patients in Oman: a retrospective study. Sultan Qaboos Univ Med J. 2025;25:839\u201346. https:\/\/doi.org\/10.18295\/2075-0528.2891.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"2639_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/medsci13030130","volume":"13","author":"AE Fitrianti","year":"2025","unstructured":"Fitrianti AE, Wardani NO, Astuti A, Anggadiredja K, Amalia L, Putri RA, et al. Cardiotoxicity in breast cancer therapy: risks, mechanisms, and prevention strategies. Med Sci. 2025;13:130. https:\/\/doi.org\/10.3390\/medsci13030130.","journal-title":"Med Sci"},{"key":"2639_CR56","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/ph18050681","volume":"18","author":"I-D Goje","year":"2025","unstructured":"Goje I-D, Goje G-I, Ordodi VL, Ciobotaru VG, Ivan VS, Buza\u0219 R, et al. Doxorubicin-induced cardiotoxicity and the emerging role of SGLT2 inhibitors: from glycemic control to cardio-oncology. Pharmaceuticals. 2025;18:681. https:\/\/doi.org\/10.3390\/ph18050681.","journal-title":"Pharmaceuticals"},{"key":"2639_CR57","doi-asserted-by":"publisher","unstructured":"Saha S, Mahapatra S, Khanra S, Mishra B, Swain B, Malhotra D, Saha S, Panda VK, Kumari K, Jena S, Thakur S, Singh PK, Kundu GC. Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives. Cancer Drug Resist. 2025. https:\/\/doi.org\/10.20517\/cdr.2025.69.","DOI":"10.20517\/cdr.2025.69"},{"key":"2639_CR58","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1097\/MS9.0000000000003121","volume":"87","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI. Oxygen gradients in tumor tissues implications for breast cancer metastasis \u2013 a narrative review. Ann Med Surg. 2025;87:3372\u201380. https:\/\/doi.org\/10.1097\/MS9.0000000000003121.","journal-title":"Ann Med Surg"},{"key":"2639_CR59","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhang H, Wang M, Schmid T, Xin Z, Kozhuharova L, Yu WK, Huang Y, Cai F, Biskup E. Hypoxia in Breast Cancer\u2014Scientific Translation to Therapeutic and Diagnostic Clinical Applications. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.652266.","DOI":"10.3389\/fonc.2021.652266"},{"key":"2639_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajco.13776","volume":"19","author":"J Methaneethorn","year":"2023","unstructured":"Methaneethorn J, Tengcharoen K, Leelakanok N, AlEjielat R. Population pharmacokinetics of doxorubicin: a systematic review. Asia Pac J Clin Oncol. 2023;19:9\u201326. https:\/\/doi.org\/10.1111\/ajco.13776.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2639_CR61","doi-asserted-by":"publisher","first-page":"104164","DOI":"10.1016\/j.jddst.2023.104164","volume":"80","author":"P Kesharwani","year":"2023","unstructured":"Kesharwani P, Sheikh A, Abourehab MAS, Salve R, Gajbhiye V. A combinatorial delivery of survivin targeted siRNA using cancer selective nanoparticles for triple negative breast cancer therapy. J Drug Deliv Sci Technol. 2023;80:104164. https:\/\/doi.org\/10.1016\/j.jddst.2023.104164.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR62","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4155\/tde-2023-0020","volume":"14","author":"JA Malik","year":"2023","unstructured":"Malik JA, Ansari JA, Ahmed S, Khan A, Ahemad N, Anwar S. Nano-drug delivery system: a promising approach against breast cancer. Ther Deliv. 2023;14:357\u201381. https:\/\/doi.org\/10.4155\/tde-2023-0020.","journal-title":"Ther Deliv"},{"key":"2639_CR63","doi-asserted-by":"publisher","unstructured":"Xing M, Yan F, Yu S, Shen P. Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: A meta-analysis of ten randomized controlled trials, PLoS One. 2015;10. https:\/\/doi.org\/10.1371\/journal.pone.0133569.","DOI":"10.1371\/journal.pone.0133569"},{"key":"2639_CR64","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1200\/OP.2023.19.11_suppl.388","volume":"19","author":"M Alhaja","year":"2023","unstructured":"Alhaja M, Chen S, Chin A, Schulte B, Legasto CS. Cardiac safety of pegylated liposomal doxorubicin after conventional doxorubicin exposure in patients with sarcoma and breast cancer. JCO Oncol Pract. 2023;19:388\u2013388. https:\/\/doi.org\/10.1200\/OP.2023.19.11_suppl.388.","journal-title":"JCO Oncol Pract"},{"key":"2639_CR65","doi-asserted-by":"publisher","first-page":"145377","DOI":"10.1016\/j.ijbiomac.2025.145377","volume":"319","author":"M Saeed","year":"2025","unstructured":"Saeed M, Altamash M, Almoyad MAA, Wahab S, Gupta G, Goh KW, et al. Transferrin-guided liposomal nanocarriers: a strategy for targeted cancer treatment. Int J Biol Macromol. 2025;319:145377. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145377.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijbiomac.2021.11.095","volume":"194","author":"SK Dubey","year":"2022","unstructured":"Dubey SK, Bhatt T, Agrawal M, Saha RN, Saraf S, Saraf S, et al. Application of chitosan modified nanocarriers in breast cancer. Int J Biol Macromol. 2022;194:521\u201338. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.11.095.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR67","doi-asserted-by":"publisher","unstructured":"Ashrafizadeh M, Hushmandi K, Mirzaei S, Bokaie S, Bigham A, Makvandi P, Rabiee N, Thakur VK, Kumar AP, Sharifi E, Varma RS, Aref AR, Wojnilowicz M, Zarrabi A, Karimi\u2010Maleh H, Voelcker NH, Mostafavi E, Orive G. Chitosan\u2010based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy. Bioeng Transl Med. 2023;8. https:\/\/doi.org\/10.1002\/btm2.10325.","DOI":"10.1002\/btm2.10325"},{"key":"2639_CR68","doi-asserted-by":"publisher","first-page":"e02178","DOI":"10.1002\/adhm.202502178","volume":"15","author":"YF Zhu","year":"2026","unstructured":"Zhu YF, He MQ, Lin CS, Ma WH, Ai Y, Wang J, et al. Multifunctional nanocarrier drug delivery systems: from diverse design to precise biomedical applications. Adv Healthc Mater. 2026;15:e02178. https:\/\/doi.org\/10.1002\/adhm.202502178.","journal-title":"Adv Healthc Mater"},{"key":"2639_CR69","doi-asserted-by":"publisher","first-page":"114895","DOI":"10.1016\/j.addr.2023.114895","volume":"198","author":"P Wen","year":"2023","unstructured":"Wen P, Ke W, Dirisala A, Toh K, Tanaka M, Li J. Stealth and pseudo-stealth nanocarriers. Adv Drug Deliv Rev. 2023;198:114895. https:\/\/doi.org\/10.1016\/j.addr.2023.114895.","journal-title":"Adv Drug Deliv Rev"},{"key":"2639_CR70","doi-asserted-by":"publisher","first-page":"23520","DOI":"10.1039\/D4RA04069D","volume":"14","author":"MM Agwa","year":"2024","unstructured":"Agwa MM, Marzouk RE, Sabra SA. Advances in active targeting of ligand-directed polymeric nanomicelles via exploiting overexpressed cellular receptors for precise nanomedicine. RSC Adv. 2024;14:23520\u201342. https:\/\/doi.org\/10.1039\/D4RA04069D.","journal-title":"RSC Adv"},{"key":"2639_CR71","doi-asserted-by":"publisher","first-page":"21365","DOI":"10.1039\/d3ra02969g","volume":"13","author":"L Hong","year":"2023","unstructured":"Hong L, Li W, Li Y, Yin S. Nanoparticle-based drug delivery systems targeting cancer cell surfaces. RSC Adv. 2023;13:21365. https:\/\/doi.org\/10.1039\/d3ra02969g.","journal-title":"RSC Adv"},{"key":"2639_CR72","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1021\/jacs.0c09029","volume":"143","author":"J Li","year":"2020","unstructured":"Li J, Kataoka K. Chemo-physical strategies to advance the in vivo functionality of targeted nanomedicine: the next generation. J Am Chem Soc. 2020;143:538\u201359. https:\/\/doi.org\/10.1021\/jacs.0c09029.","journal-title":"J Am Chem Soc"},{"key":"2639_CR73","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/pharmaceutics17111414","volume":"17","author":"HU P\u00e9rez-Ortega","year":"2025","unstructured":"P\u00e9rez-Ortega HU, C\u00f3rdova-Esp\u00edritu RR, Cano-Serrano S, Garc\u00eda-Gonz\u00e1lez E, Bravo-S\u00e1nchez MG, del C. Orozco-Mosqueda M, et al. Camptothecin in cancer therapy: current challenges and emerging strategies with nanoemulsions. Pharmaceutics. 2025;17:1414. https:\/\/doi.org\/10.3390\/pharmaceutics17111414.","journal-title":"Pharmaceutics"},{"key":"2639_CR74","doi-asserted-by":"publisher","first-page":"126400","DOI":"10.1016\/j.ijpharm.2025.126400","volume":"687","author":"S Chennamsetty","year":"2026","unstructured":"Chennamsetty S, Keerikkadu M, Shetty A, Bangera PD, Tippavajhala VK, Rathnanand M. Biohybrid nanocarriers for targeted drug delivery by integrating biological interfaces with synthetic platforms for site-specific therapeutics. Int J Pharm. 2026;687:126400. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.126400.","journal-title":"Int J Pharm"},{"key":"2639_CR75","doi-asserted-by":"publisher","first-page":"319","DOI":"10.20892\/j.issn.2095-3941.2020.0496","volume":"18","author":"X Zhao","year":"2021","unstructured":"Zhao X, Bai J, Yang W. Stimuli-responsive nanocarriers for therapeutic applications in cancer. Cancer Biol Med. 2021;18:319. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0496.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"2639_CR76","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","volume":"24","author":"H Sabit","year":"2025","unstructured":"Sabit H, Pawlik TM, Radwan F, Abdel-Hakeem M, Abdel-Ghany S, Wadan AHS, et al. Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol Cancer. 2025;24(1):160. https:\/\/doi.org\/10.1186\/s12943-025-02357-z.","journal-title":"Mol Cancer"},{"key":"2639_CR77","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/polym13111717","volume":"13","author":"Y Herdiana","year":"2021","unstructured":"Herdiana Y, Wathoni N, Shamsuddin S, Joni IM, Muchtaridi M. Chitosan-based nanoparticles of targeted drug delivery system in breast cancer treatment. Polymers (Basel). 2021;13:1717. https:\/\/doi.org\/10.3390\/polym13111717.","journal-title":"Polymers (Basel)"},{"key":"2639_CR78","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/pharmaceutics15030879","volume":"15","author":"Y Herdiana","year":"2023","unstructured":"Herdiana Y, Wathoni N, Gozali D, Shamsuddin S, Muchtaridi M. Chitosan-based nano-smart drug delivery system in breast cancer therapy. Pharmaceutics. 2023;15:879. https:\/\/doi.org\/10.3390\/pharmaceutics15030879.","journal-title":"Pharmaceutics"},{"key":"2639_CR79","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3390\/pharmaceutics15071849","volume":"15","author":"M Karayianni","year":"2023","unstructured":"Karayianni M, Sentoukas T, Skandalis A, Pippa N, Pispas S. Chitosan-based nanoparticles for nucleic acid delivery: technological aspects, applications, and future perspectives. Pharmaceutics. 2023;15:1849. https:\/\/doi.org\/10.3390\/pharmaceutics15071849.","journal-title":"Pharmaceutics"},{"key":"2639_CR80","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3390\/POLYM17111453","volume":"17","author":"A Stefanache","year":"2025","unstructured":"Stefanache A, Lungu II, Anton N, Damir D, Gutu C, Olaru I, et al. Chitosan Nanoparticle-Based Drug Delivery Systems: Advances, Challenges, and Future Perspectives. Polym. 2025;17:1453. https:\/\/doi.org\/10.3390\/POLYM17111453.","journal-title":"Polym"},{"key":"2639_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2288892","volume":"2022","author":"HT-T Nguyen","year":"2022","unstructured":"Nguyen HT-T, Tran TN, Ha AC, Huynh PD. Impact of deacetylation degree on properties of chitosan for formation of electrosprayed nanoparticles. J Nanotechnol. 2022;2022:1\u201311. https:\/\/doi.org\/10.1155\/2022\/2288892.","journal-title":"J Nanotechnol"},{"key":"2639_CR82","doi-asserted-by":"publisher","unstructured":"Frigaard J, Jensen JL, Galtung HK, Hiorth M. The Potential of Chitosan in Nanomedicine: An Overview of the Cytotoxicity of Chitosan Based Nanoparticles. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.880377.","DOI":"10.3389\/fphar.2022.880377"},{"key":"2639_CR83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biotech13010006","volume":"13","author":"T Takeuchi","year":"2024","unstructured":"Takeuchi T, Oyama M, Hatanaka T. Effect of chitosan degradation products, glucosamine and chitosan oligosaccharide, on osteoclastic differentiation. Biotech. 2024;13:6. https:\/\/doi.org\/10.3390\/biotech13010006.","journal-title":"Biotech"},{"key":"2639_CR84","doi-asserted-by":"publisher","first-page":"105994","DOI":"10.1016\/j.jddst.2024.105994","volume":"99","author":"H Kordbacheh","year":"2024","unstructured":"Kordbacheh H, Bahmani E, Bybordi S, Rezaee A, Dehghanian Z, Ehsanfar N, et al. Co-delivery of Bcl-2 siRNA and doxorubicin using liposome-incorporated poly(\u03b5-caprolactone) \/chitosan nanofibers for the treatment of lung cancer. J Drug Deliv Sci Technol. 2024;99:105994. https:\/\/doi.org\/10.1016\/j.jddst.2024.105994.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR85","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/pharmaceutics15020503","volume":"15","author":"J Kurczewska","year":"2023","unstructured":"Kurczewska J. Chitosan-based nanoparticles with optimized parameters for targeted delivery of a specific anticancer drug\u2014a comprehensive review. Pharmaceutics. 2023;15:503. https:\/\/doi.org\/10.3390\/pharmaceutics15020503.","journal-title":"Pharmaceutics"},{"key":"2639_CR86","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.3390\/molecules28114328","volume":"28","author":"N Van Bavel","year":"2023","unstructured":"Van Bavel N, Issler T, Pang L, Anikovskiy M, Prenner EJ. A simple method for synthesis of chitosan nanoparticles with ionic gelation and homogenization. Molecules. 2023;28:4328. https:\/\/doi.org\/10.3390\/molecules28114328.","journal-title":"Molecules"},{"key":"2639_CR87","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/md21040211","volume":"21","author":"B Sachdeva","year":"2023","unstructured":"Sachdeva B, Sachdeva P, Negi A, Ghosh S, Han S, Dewanjee S, et al. Chitosan nanoparticles-based cancer drug delivery: application and challenges. Mar Drugs. 2023;21:211. https:\/\/doi.org\/10.3390\/md21040211.","journal-title":"Mar Drugs"},{"key":"2639_CR88","doi-asserted-by":"publisher","unstructured":"Ding J, Guo Y. Recent Advances in Chitosan and its Derivatives in Cancer Treatment. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.888740.","DOI":"10.3389\/fphar.2022.888740"},{"key":"2639_CR89","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/molecules29010031","volume":"29","author":"H Imran","year":"2023","unstructured":"Imran H, Tang Y, Wang S, Yan X, Liu C, Guo L, et al. Optimized DOX drug deliveries via chitosan-mediated nanoparticles and stimuli responses in cancer chemotherapy: a review. Molecules. 2023;29:31. https:\/\/doi.org\/10.3390\/molecules29010031.","journal-title":"Molecules"},{"key":"2639_CR90","doi-asserted-by":"publisher","unstructured":"Lisik BP, Sado A, Rogowska W, Sroczy\u0144ski JW, Rogowski O, Rogowski O. Nanoparticles in targeted breast cancer therapy \u2014 advances and challenges. Oncol Clin Pract. 2025. https:\/\/doi.org\/10.5603\/ocp.106843.","DOI":"10.5603\/ocp.106843"},{"key":"2639_CR91","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1080\/10717544.2021.1960926","volume":"28","author":"F Guo","year":"2021","unstructured":"Guo F, Yu N, Jiao Y, Hong W, Zhou K, Ji X, et al. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer. Drug Deliv. 2021;28:1709\u201321. https:\/\/doi.org\/10.1080\/10717544.2021.1960926.","journal-title":"Drug Deliv"},{"key":"2639_CR92","doi-asserted-by":"publisher","first-page":"109049","DOI":"10.1016\/j.carres.2024.109049","volume":"536","author":"MG Antoniraj","year":"2024","unstructured":"Antoniraj MG, Dhayanandamoorthy Y, Ponnuchamy K, Kandasamy R, Pandima Devi K. Study the anticancer efficacy of doxorubicin-loaded redox-responsive chitosan-derived nanoparticles in the MDA-MB-231 cell line. Carbohydr Res. 2024;536:109049. https:\/\/doi.org\/10.1016\/j.carres.2024.109049.","journal-title":"Carbohydr Res"},{"key":"2639_CR93","doi-asserted-by":"publisher","first-page":"148220","DOI":"10.1016\/j.ijbiomac.2025.148220","volume":"330","author":"L Pakjo","year":"2025","unstructured":"Pakjo L, Teimuri-Mofrad R, Fathi M. cRGD (\u03b1v\u03b23 integrin receptor)-functional thermo\/pH sensitive chitosan copolymer magnetic nanoparticles for targeted therapy of breast cancer. Int J Biol Macromol. 2025;330:148220. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148220.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR94","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.xphs.2024.02.005","volume":"113","author":"M Imanimoghadam","year":"2024","unstructured":"Imanimoghadam M, Yaghoobi E, Alizadeh F, Ramezani M, Alibolandi M, Abnous K, et al. Improving chemotherapy effectiveness: utilizing CuS nanoparticles coated with AS1411 aptamer and chitosan for targeted delivery of doxorubicin to cancerous cells. J Pharm Sci. 2024;113:1865\u201373. https:\/\/doi.org\/10.1016\/j.xphs.2024.02.005.","journal-title":"J Pharm Sci"},{"key":"2639_CR95","doi-asserted-by":"publisher","first-page":"119122","DOI":"10.1016\/j.ijpharm.2020.119122","volume":"578","author":"J Li","year":"2020","unstructured":"Li J, Li M, Tian L, Qiu Y, Yu Q, Wang X, et al. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy. Int J Pharm. 2020;578:119122. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119122.","journal-title":"Int J Pharm"},{"key":"2639_CR96","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijbiomac.2019.06.055","volume":"136","author":"A Kefayat","year":"2019","unstructured":"Kefayat A, Vaezifar S. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice. Int J Biol Macromol. 2019;136:48\u201356. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.06.055.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijbiomac.2021.06.014","volume":"184","author":"O Helmi","year":"2021","unstructured":"Helmi O, Elshishiny F, Mamdouh W. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies. Int J Biol Macromol. 2021;184:325\u201338. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.06.014.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR98","doi-asserted-by":"publisher","first-page":"125640","DOI":"10.1016\/j.ijbiomac.2023.125640","volume":"246","author":"A Alioghli Ziaei","year":"2023","unstructured":"Alioghli Ziaei A, Erfan-Niya H, Fathi M, Amiryaghoubi N. In situ forming alginate\/gelatin hybrid hydrogels containing doxorubicin loaded chitosan\/AuNPs nanogels for the local therapy of breast cancer. Int J Biol Macromol. 2023;246:125640. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125640.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR99","doi-asserted-by":"publisher","first-page":"131428","DOI":"10.1016\/j.ijbiomac.2024.131428","volume":"267","author":"J Li","year":"2024","unstructured":"Li J, Wen Q, Dai J, Wang B, Lu Y, Wu Z, et al. An oral bioactive chitosan-decorated doxorubicin nanoparticles\/bacteria bioconjugates enhance chemotherapy efficacy in an in-situ breast cancer model. Int J Biol Macromol. 2024;267:131428. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.131428.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR100","doi-asserted-by":"publisher","first-page":"131971","DOI":"10.1016\/j.ijbiomac.2024.131971","volume":"269","author":"N Dashti","year":"2024","unstructured":"Dashti N, Akbari V, Varshosaz J, Soleimanbeigi M, Rostami M. Co-delivery of carboplatin and doxorubicin using ZIF-8 coated chitosan-poly(N-isopropyl acrylamide) nanoparticles through a dual pH\/thermo responsive strategy to breast cancer cells. Int J Biol Macromol. 2024;269:131971. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.131971.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR101","doi-asserted-by":"publisher","first-page":"135904","DOI":"10.1016\/j.ijbiomac.2024.135904","volume":"281","author":"S Nalinbenjapun","year":"2024","unstructured":"Nalinbenjapun S, Sripetthong S, Basit A, Suksuwan A, Sajomsang W, Ovatlarnporn C. Fabrication of curcumin-loaded nano-micelles based on quercetin-quarternary ammonium-chitosan (Qu-QCS) conjugate and evaluation of synergistic effect with doxorubicin against breast cancer. Int J Biol Macromol. 2024;281:135904. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.135904.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR102","doi-asserted-by":"publisher","first-page":"141191","DOI":"10.1016\/j.ijbiomac.2025.141191","volume":"305","author":"A Rakhshani","year":"2025","unstructured":"Rakhshani A, Maghsoudian S, Ejarestaghi NM, Yousefi M, Yoosefi S, Asadzadeh N, et al. Polyethylene oxide-chitosan-doxorubicin\/polycaprolactone-chitosan-curcumin pH-sensitive core\/shell nanofibrous mats for the treatment of breast cancer: fabrication, characterization and in vitro and in vivo evaluation. Int J Biol Macromol. 2025;305:141191. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.141191.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR103","doi-asserted-by":"publisher","first-page":"144381","DOI":"10.1016\/j.ijbiomac.2025.144381","volume":"315","author":"AA Ziaei","year":"2025","unstructured":"Ziaei AA, Erfan-Niya H, Fathi M, Amiryaghoubi N. In situ fast gelling modified polyvinyl alcohol\/polyethylene glycol hybrid hydrogels incorporating doxorubicin-loaded chitosan\/AuNPs nanogels for localized treatment of breast cancer. Int J Biol Macromol. 2025;315:144381. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.144381.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR104","doi-asserted-by":"publisher","first-page":"145874","DOI":"10.1016\/j.ijbiomac.2025.145874","volume":"320","author":"TK Rajwar","year":"2025","unstructured":"Rajwar TK, Sahoo RK, Halder J, Mishra A, Satapathy B, Saha I, et al. Doxorubicin loaded salicylic acid crosslinked chitosan nanoparticles as postsurgical implants for breast cancer. Int J Biol Macromol. 2025;320:145874. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145874.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR105","doi-asserted-by":"publisher","first-page":"115206","DOI":"10.1016\/j.carbpol.2019.115206","volume":"225","author":"Y Wang","year":"2019","unstructured":"Wang Y, Qian J, Yang M, Xu W, Wang J, Hou G, et al. Doxorubicin\/cisplatin co-loaded hyaluronic acid\/chitosan-based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer. Carbohydr Polym. 2019;225:115206. https:\/\/doi.org\/10.1016\/j.carbpol.2019.115206.","journal-title":"Carbohydr Polym"},{"key":"2639_CR106","doi-asserted-by":"publisher","first-page":"117631","DOI":"10.1016\/j.carbpol.2021.117631","volume":"257","author":"M Abasalta","year":"2021","unstructured":"Abasalta M, Asefnejad A, Khorasani MT, Saadatabadi AR. Fabrication of carboxymethyl chitosan\/poly(\u03b5-caprolactone)\/doxorubicin\/nickel ferrite core-shell fibers for controlled release of doxorubicin against breast cancer. Carbohydr Polym. 2021;257:117631. https:\/\/doi.org\/10.1016\/j.carbpol.2021.117631.","journal-title":"Carbohydr Polym"},{"key":"2639_CR107","doi-asserted-by":"publisher","first-page":"114122","DOI":"10.1016\/j.colsurfb.2024.114122","volume":"243","author":"A Taghikhani","year":"2024","unstructured":"Taghikhani A, Babazadeh M, Davaran S, Ghasemi E. Facile preparation of a pH-sensitive biocompatible nanocarrier based on magnetic layered double hydroxides\/Cu MOFs-chitosan crosslinked \u043a-carrageenan for controlled doxorubicin delivery to breast cancer cells. Colloids Surf B Biointerfaces. 2024;243:114122. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.114122.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2639_CR108","doi-asserted-by":"publisher","first-page":"111526","DOI":"10.1016\/j.msec.2020.111526","volume":"118","author":"Z Shakeran","year":"2021","unstructured":"Shakeran Z, Keyhanfar M, Varshosaz J, Sutherland DS. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment. Mater Sci Eng C Mater Biol. 2021;118:111526. https:\/\/doi.org\/10.1016\/j.msec.2020.111526.","journal-title":"Mater Sci Eng C Mater Biol"},{"key":"2639_CR109","doi-asserted-by":"publisher","first-page":"101423","DOI":"10.1016\/j.jddst.2019.101423","volume":"55","author":"MA Abdel-Hakeem","year":"2020","unstructured":"Abdel-Hakeem MA, Abdel-Haseb OM, Abdel-Ghany SE, Cevik E, Sabit H. Doxorubicin loaded on chitosan-protamine nanoparticles triggers apoptosis via downregulating Bcl-2 in breast cancer cells. J Drug Deliv Sci Technol. 2020;55:101423. https:\/\/doi.org\/10.1016\/j.jddst.2019.101423.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR110","doi-asserted-by":"publisher","first-page":"102978","DOI":"10.1016\/j.jddst.2021.102978","volume":"67","author":"J Akinyelu","year":"2022","unstructured":"Akinyelu J, Oladimeji O, Daniels A, Singh M. Folate-targeted doxorubicin delivery to breast and cervical cancer cells using a chitosan-gold nano-delivery system. J Drug Deliv Sci Technol. 2022;67:102978. https:\/\/doi.org\/10.1016\/j.jddst.2021.102978.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR111","doi-asserted-by":"publisher","first-page":"107213","DOI":"10.1016\/j.jddst.2025.107213","volume":"111","author":"BN Sahoo","year":"2025","unstructured":"Sahoo BN, Joshi B, Rana S, Rathnam VSS, Sahare T, Joshi A. Synergistic anticancer effect of Doxorubicin and Tamoxifen in chitosan nanoparticles for ER-positive breast cancer. J Drug Deliv Sci Technol. 2025;111:107213. https:\/\/doi.org\/10.1016\/j.jddst.2025.107213.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR112","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.arabjc.2018.04.012","volume":"13","author":"NB Varukattu","year":"2020","unstructured":"Varukattu NB, Vivek R, Rejeeth C, Thangam R, Ponraj T, Sharma A, et al. Nanostructured pH-responsive biocompatible chitosan coated copper oxide nanoparticles: a polymeric smart intracellular delivery system for doxorubicin in breast cancer cells. Arab J Chem. 2020;13:2276\u201386. https:\/\/doi.org\/10.1016\/j.arabjc.2018.04.012.","journal-title":"Arab J Chem"},{"key":"2639_CR113","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.colcom.2018.12.002","volume":"28","author":"JG Rosch","year":"2019","unstructured":"Rosch JG, Winter H, DuRoss AN, Sahay G, Sun C. Inverse-micelle synthesis of doxorubicin-loaded alginate\/chitosan nanoparticles and in vitro assessment of breast cancer cytotoxicity. Colloids Interface Sci Commun. 2019;28:69\u201374. https:\/\/doi.org\/10.1016\/j.colcom.2018.12.002.","journal-title":"Colloids Interface Sci Commun"},{"key":"2639_CR114","doi-asserted-by":"publisher","unstructured":"Azmoudeh A, Sari S, T\u00fcrk M, Moral S, Kaya \u00d6, Kahveci MU, Doganay GD, Ku\u015fcu M, Erkol N, A\u011fao\u011fullar\u0131 D. Layer-by-layer assembled hyaluronic acid\/chitosan-coated Fe3O4@rGO nanoparticles: Synthesis and characterization for doxorubicin delivery in breast cancer cells. J Sci Adv Mater Devices. 2025;10. https:\/\/doi.org\/10.1016\/j.jsamd.2025.101012.","DOI":"10.1016\/j.jsamd.2025.101012"},{"key":"2639_CR115","doi-asserted-by":"publisher","unstructured":"Soman S, Kulkarni S, Vineeth P, George SD, Mutalik S. Harnessing nanotechnology for breast cancer management: UiO-66 (NH2) metal-organic frameworks functionalized with chitosan and folic acid for the efficient delivery of doxorubicin. Nano-Structures Nano-Objects. 2024;40. https:\/\/doi.org\/10.1016\/j.nanoso.2024.101360.","DOI":"10.1016\/j.nanoso.2024.101360"},{"key":"2639_CR116","doi-asserted-by":"publisher","first-page":"33952","DOI":"10.1039\/D4RA06253A","volume":"14","author":"GP Sahoo","year":"2024","unstructured":"Sahoo GP, Rai VK, Pradhan D, Halder J, Rajwar TK, Mahanty R, et al. A doxorubicin loaded chitosan\u2013poloxamer in situ implant for the treatment of breast cancer. RSC Adv. 2024;14:33952\u201367. https:\/\/doi.org\/10.1039\/D4RA06253A.","journal-title":"RSC Adv"},{"key":"2639_CR117","doi-asserted-by":"publisher","unstructured":"Zhang H, Xue Q, Zhou Z, He N, Li S, Zhao C. Co-delivery of doxorubicin and hydroxychloroquine via chitosan\/alginate nanoparticles for blocking autophagy and enhancing chemotherapy in breast cancer therapy. Front Pharmacol. 2023;14. https:\/\/doi.org\/10.3389\/fphar.2023.1176232.","DOI":"10.3389\/fphar.2023.1176232"},{"key":"2639_CR118","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.molpharmaceut.1c00459","volume":"19","author":"X Yang","year":"2022","unstructured":"Yang X, Shang P, Ji J, Malichewe C, Yao Z, Liao J, et al. Hyaluronic acid-modified nanoparticles self-assembled from linoleic acid-conjugated chitosan for the codelivery of miR34a and doxorubicin in resistant breast cancer. Mol Pharm. 2022;19:2\u201317. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00459.","journal-title":"Mol Pharm"},{"key":"2639_CR119","doi-asserted-by":"publisher","unstructured":"Katuwavila P, Perera ADLC, Samarakoon SR, Soysa P, Karunaratne V, Amaratunga GAJ, Karunaratne DN. Chitosan-Alginate Nanoparticle System Efficiently Delivers Doxorubicin to MCF-7 Cells. J Nanomater. 2016;2016. https:\/\/doi.org\/10.1155\/2016\/3178904.","DOI":"10.1155\/2016\/3178904"},{"key":"2639_CR120","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3390\/pharmaceutics13111829","volume":"13","author":"K Ganesan","year":"2021","unstructured":"Ganesan K, Wang Y, Gao F, Liu Q, Zhang C, Li P, et al. Targeting engineered nanoparticles for breast cancer therapy. Pharmaceutics. 2021;13:1829. https:\/\/doi.org\/10.3390\/pharmaceutics13111829.","journal-title":"Pharmaceutics"},{"key":"2639_CR121","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/biomedicines9020114","volume":"9","author":"S Jahan","year":"2021","unstructured":"Jahan S, Karim ME, Chowdhury EH. Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics. Biomedicines. 2021;9:114. https:\/\/doi.org\/10.3390\/biomedicines9020114.","journal-title":"Biomedicines"},{"key":"2639_CR122","doi-asserted-by":"publisher","unstructured":"Kesharwani P, Chadar R, Sheikh A, Rizg WY, Safhi AY. CD44-Targeted Nanocarrier for Cancer Therapy. Front Pharmacol. 2022;12. https:\/\/doi.org\/10.3389\/fphar.2021.800481.","DOI":"10.3389\/fphar.2021.800481"},{"key":"2639_CR123","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.2174\/0929867330666230416153352","volume":"31","author":"C Lai","year":"2024","unstructured":"Lai C, Lin S, Liu W, Jin Y. Research progress of chitosan-based multifunctional nanoparticles in cancer targeted therapy. Curr Med Chem. 2024;31:3074\u201392. https:\/\/doi.org\/10.2174\/0929867330666230416153352.","journal-title":"Curr Med Chem"},{"key":"2639_CR124","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41523-020-0147-1","volume":"6","author":"N Norton","year":"2020","unstructured":"Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, et al. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020;6:4. https:\/\/doi.org\/10.1038\/s41523-020-0147-1.","journal-title":"NPJ Breast Cancer"},{"key":"2639_CR125","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/cancers12020278","volume":"12","author":"E Gaio","year":"2020","unstructured":"Gaio E, Conte C, Esposito D, Reddi E, Quaglia F, Moret F. CD44 Targeting Mediated by Polymeric Nanoparticles and Combination of Chlorine TPCS2a-PDT and Docetaxel-Chemotherapy for Efficient Killing of Breast Differentiated and Stem Cancer Cells In Vitro. Cancers (Basel). 2020;12:278. https:\/\/doi.org\/10.3390\/cancers12020278.","journal-title":"Cancers (Basel)"},{"key":"2639_CR126","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jncc.2024.12.008","volume":"5","author":"J Zhao","year":"2025","unstructured":"Zhao J, Zhou Z, Saw PE, Song E. Silver jubilee of HER2 targeting: a clinical success in breast cancer. J Natl Cancer Cent. 2025;5:379. https:\/\/doi.org\/10.1016\/j.jncc.2024.12.008.","journal-title":"J Natl Cancer Cent"},{"key":"2639_CR127","doi-asserted-by":"publisher","unstructured":"Bogdanovi\u0107 B, Fagret D, Ghezzi C, Montemagno C. Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine\u2013Glycine\u2013Aspartate) Strategies. Pharm. 2024;17(2024). https:\/\/doi.org\/10.3390\/ph17111556.","DOI":"10.3390\/ph17111556"},{"key":"2639_CR128","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-18-0652","volume":"24","author":"A Cheung","year":"2018","unstructured":"Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, et al. Anti-folate receptor alpha\u2013directed antibody therapies restrict the growth of triple-negative breast cancer. Clin Cancer Res. 2018;24:5098\u2013111. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0652.","journal-title":"Clin Cancer Res"},{"key":"2639_CR129","doi-asserted-by":"publisher","unstructured":"Chen CI, Li WS, Chen HP, Liu KW, Tsai CJ, Hung WJ, Yang CC. High Expression of Folate Receptor Alpha (FOLR1) is Associated With Aggressive Tumor Behavior, Poor Response to Chemoradiotherapy, and Worse Survival in Rectal Cancer. Technol Cancer Res Treat. 2022;21. https:\/\/doi.org\/10.1177\/15330338221141795.","DOI":"10.1177\/15330338221141795"},{"key":"2639_CR130","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/pharmaceutics15010110","volume":"15","author":"HHM San","year":"2022","unstructured":"San HHM, Alcantara KP, Bulatao BPI, Sorasitthiyanukarn FN, Nalinratana N, Suksamrarn A, et al. Folic acid-grafted chitosan-alginate nanocapsules as effective targeted nanocarriers for delivery of turmeric oil for breast cancer therapy. Pharmaceutics. 2022;15:110. https:\/\/doi.org\/10.3390\/pharmaceutics15010110.","journal-title":"Pharmaceutics"},{"key":"2639_CR131","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/pharmaceutics14010053","volume":"14","author":"C Joseph","year":"2021","unstructured":"Joseph C, Daniels A, Singh S, Singh M. Histidine-tagged folate-targeted gold nanoparticles for enhanced transgene expression in breast cancer cells in vitro. Pharmaceutics. 2021;14:53. https:\/\/doi.org\/10.3390\/pharmaceutics14010053.","journal-title":"Pharmaceutics"},{"key":"2639_CR132","doi-asserted-by":"publisher","first-page":"33723","DOI":"10.1039\/D1RA04591A","volume":"11","author":"R Singh","year":"2021","unstructured":"Singh R, Kumar B, Sahu RK, Kumari S, Jha CB, Singh N, et al. Development of a pH-sensitive functionalized metal organic framework: in vitro study for simultaneous delivery of doxorubicin and cyclophosphamide in breast cancer. RSC Adv. 2021;11:33723\u201333. https:\/\/doi.org\/10.1039\/D1RA04591A.","journal-title":"RSC Adv"},{"key":"2639_CR133","doi-asserted-by":"publisher","first-page":"10127","DOI":"10.2147\/IJN.S534422","volume":"20","author":"X-R Jiang","year":"2025","unstructured":"Jiang X-R, Mi J, Wang Y, Yin M, Tong Y, Zhu Y. Application of metal-organic frameworks nanoparticles in the diagnosis and treatment of breast cancer. Int J Nanomedicine. 2025;20:10127\u201349. https:\/\/doi.org\/10.2147\/IJN.S534422.","journal-title":"Int J Nanomedicine"},{"key":"2639_CR134","doi-asserted-by":"publisher","unstructured":"Akbar MU, Khattak S, Khan MI, Saddozai UAK, Ali N, AlAsmari AF, Zaheer M, Badar M. A pH-responsive bi-MIL-88B MOF coated with folic acid-conjugated chitosan as a promising nanocarrier for targeted drug delivery of 5-Fluorouracil. Front Pharmacol. 2023;14. https:\/\/doi.org\/10.3389\/fphar.2023.1265440.","DOI":"10.3389\/fphar.2023.1265440"},{"key":"2639_CR135","doi-asserted-by":"publisher","unstructured":"Saha T, Lukong KE. Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.856974.","DOI":"10.3389\/fonc.2022.856974"},{"key":"2639_CR136","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/omi.2021.0025","volume":"25","author":"K Dzobo","year":"2021","unstructured":"Dzobo K, Sinkala M. Cancer stem cell marker CD44 plays multiple key roles in human cancers: immune suppression\/evasion, drug resistance, epithelial-mesenchymal transition, and metastasis. Omi A J Integr Biol. 2021;25:313\u201332. https:\/\/doi.org\/10.1089\/omi.2021.0025.","journal-title":"Omi A J Integr Biol"},{"key":"2639_CR137","doi-asserted-by":"publisher","unstructured":"Jia Y, Chen S, Wang C, Sun T, Yang L. Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances. Front Bioeng Biotechnol. 2022;10. https:\/\/doi.org\/10.3389\/fbioe.2022.990145.","DOI":"10.3389\/fbioe.2022.990145"},{"key":"2639_CR138","doi-asserted-by":"publisher","first-page":"140144","DOI":"10.1016\/j.ijbiomac.2025.140144","volume":"301","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Cao Y, Yao Y, Zhang D, Wang Y. Chitosan and hyaluronic acid in breast cancer treatment: anticancer efficacy and nanoparticle and hydrogel development. Int J Biol Macromol. 2025;301:140144. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.140144.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR139","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.colsurfb.2015.09.043","volume":"136","author":"P Kesharwani","year":"2015","unstructured":"Kesharwani P, Xie L, Banerjee S, Mao G, Padhye S, Sarkar FH, et al. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Colloids Surf B Biointerfaces. 2015;136:413\u201323. https:\/\/doi.org\/10.1016\/j.colsurfb.2015.09.043.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2639_CR140","doi-asserted-by":"publisher","unstructured":"Kaurav H, Verma D, Bansal A, Kapoor DN, Sheth S. Progress in drug delivery and diagnostic applications of carbon dots: a systematic review. Front Chem. 2023;11. https:\/\/doi.org\/10.3389\/fchem.2023.1227843.","DOI":"10.3389\/fchem.2023.1227843"},{"key":"2639_CR141","doi-asserted-by":"publisher","first-page":"102680","DOI":"10.1016\/j.jddst.2021.102680","volume":"65","author":"S Hatamie","year":"2021","unstructured":"Hatamie S, Balasi ZM, Ahadian MM, Mortezazadeh T, Shams F, Hosseinzadeh S. Hyperthermia of breast cancer tumor using graphene oxide-cobalt ferrite magnetic nanoparticles in mice. J Drug Deliv Sci Technol. 2021;65:102680. https:\/\/doi.org\/10.1016\/j.jddst.2021.102680.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR142","doi-asserted-by":"publisher","unstructured":"Aggarwal R, Magar A, Dongsar TT, Dongsar TS, Abdullah Almoyad MA, Wahab S, Goh KW, Kesharwani P. Magnetic nanoparticles in cancer nanomedicine: advances in targeting, hyperthermia, and theranostics. Int J Pharm. 2026;689. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.126483.","DOI":"10.1016\/j.ijpharm.2025.126483"},{"key":"2639_CR143","doi-asserted-by":"publisher","unstructured":"Kourti M, Theodorakis A, Skouras A, Chrissopoulou K, Anastasiadis SH, Stylianakis MM. Capitalization of Graphene\/Chitosan Nanocomposites as Intriguing Vehicles for Targeted Anti\u2010Cancer Drug Delivery. Adv Ther. 2023;6. https:\/\/doi.org\/10.1002\/adtp.202300177.","DOI":"10.1002\/adtp.202300177"},{"key":"2639_CR144","doi-asserted-by":"publisher","first-page":"114628","DOI":"10.1016\/j.microc.2025.114628","volume":"216","author":"MS Ali","year":"2025","unstructured":"Ali MS, Alsayari A, Wahab S, Gupta G, Goh KW, Kesharwani P. Advances in iron oxide nanoparticles for targeted breast cancer therapy: a promising nanomedicine approach. Microchem J. 2025;216:114628. https:\/\/doi.org\/10.1016\/j.microc.2025.114628.","journal-title":"Microchem J"},{"key":"2639_CR145","doi-asserted-by":"publisher","first-page":"15812","DOI":"10.3390\/ijms242115812","volume":"24","author":"N Cirillo","year":"2023","unstructured":"Cirillo N. The hyaluronan\/CD44 axis: a double-edged sword in cancer. Int J Mol Sci. 2023;24:15812. https:\/\/doi.org\/10.3390\/ijms242115812.","journal-title":"Int J Mol Sci"},{"key":"2639_CR146","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1200\/OP.21.00020","volume":"17","author":"S Pernas","year":"2021","unstructured":"Pernas S, Tolaney SM. Management of early-stage human epidermal growth factor receptor 2\u2013positive breast cancer. JCO Oncol Pract. 2021;17:320\u201330. https:\/\/doi.org\/10.1200\/OP.21.00020.","journal-title":"JCO Oncol Pract"},{"key":"2639_CR147","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3390\/cancers14102424","volume":"14","author":"L Sitia","year":"2022","unstructured":"Sitia L, Sevieri M, Signati L, Bonizzi A, Chesi A, Mainini F, et al. HER-2-targeted nanoparticles for breast cancer diagnosis and treatment. Cancers (Basel). 2022;14:2424. https:\/\/doi.org\/10.3390\/cancers14102424.","journal-title":"Cancers (Basel)"},{"key":"2639_CR148","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.1021\/nn4047925","volume":"7","author":"ZJ Deng","year":"2013","unstructured":"Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano. 2013;7:9571\u201384. https:\/\/doi.org\/10.1021\/nn4047925.","journal-title":"ACS Nano"},{"key":"2639_CR149","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.3390\/polym14163410","volume":"14","author":"LE Puluhulawa","year":"2022","unstructured":"Puluhulawa LE, Joni IM, Elamin KM, Mohammed AFA, Muchtaridi M, Wathoni N. Chitosan\u2013hyaluronic acid nanoparticles for active targeting in cancer therapy. Polymers (Basel). 2022;14:3410. https:\/\/doi.org\/10.3390\/polym14163410.","journal-title":"Polymers (Basel)"},{"key":"2639_CR150","doi-asserted-by":"publisher","first-page":"189","DOI":"10.7150\/thno\/v01p0189","volume":"1","author":"K Chen","year":"2011","unstructured":"Chen K, Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics. 2011;1:189\u2013200. https:\/\/doi.org\/10.7150\/thno\/v01p0189.","journal-title":"Theranostics"},{"key":"2639_CR151","doi-asserted-by":"publisher","first-page":"105663","DOI":"10.1016\/j.jddst.2024.105663","volume":"96","author":"P Kesharwani","year":"2024","unstructured":"Kesharwani P, Chandra J, Karim S, Gupta G, Karwasra R, Sharma A. \u0391v\u03b23 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment. J Drug Deliv Sci Technol. 2024;96:105663. https:\/\/doi.org\/10.1016\/j.jddst.2024.105663.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR152","doi-asserted-by":"publisher","unstructured":"Javid H, Oryani MA, Rezagholinejad N, Esparham A, Tajaldini M, Karimi\u2010Shahri M. <scp>RGD<\/scp> peptide in cancer targeting: Benefits, challenges, solutions, and possible <scp>integrin\u2013RGD<\/scp> interactions. Cancer Med. 2024;13. https:\/\/doi.org\/10.1002\/cam4.6800.","DOI":"10.1002\/cam4.6800"},{"key":"2639_CR153","doi-asserted-by":"publisher","unstructured":"Van den Avont A, Sharma-Walia N. Anti-nucleolin aptamer AS1411: an advancing therapeutic. Front Mol Biosci. 2023;10. https:\/\/doi.org\/10.3389\/fmolb.2023.1217769.","DOI":"10.3389\/fmolb.2023.1217769"},{"key":"2639_CR154","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s13346-025-01930-9","volume":"16","author":"TP Ribeiro","year":"2026","unstructured":"Ribeiro TP, Gomes FL, Vilarinho R, Salgado C, Martins MCL, Moreira JA, et al. Thermoresponsive nanoparticles for targeted and controlled delivery of doxorubicin in triple negative breast cancer: a 2D and 3D in vitro evaluation. Drug Deliv Transl Res. 2026;16:108\u201323. https:\/\/doi.org\/10.1007\/s13346-025-01930-9.","journal-title":"Drug Deliv Transl Res"},{"key":"2639_CR155","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.smaim.2022.09.004","volume":"4","author":"RA Mustafa","year":"2023","unstructured":"Mustafa RA, Ran M, Wang Y, Yan J, Zhang Y, Rosenholm JM, et al. A pH\/temperature responsive nanocomposite for chemo-photothermal synergistic cancer therapy. Smart Mater Med. 2023;4:199\u2013211. https:\/\/doi.org\/10.1016\/j.smaim.2022.09.004.","journal-title":"Smart Mater Med"},{"key":"2639_CR156","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1021\/nn5002112","volume":"8","author":"L Guo","year":"2014","unstructured":"Guo L, Yan DD, Yang D, Li Y, Wang X, Zalewski O, et al. Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. ACS Nano. 2014;8:5670\u201381. https:\/\/doi.org\/10.1021\/nn5002112.","journal-title":"ACS Nano"},{"key":"2639_CR157","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.mtla.2021.101195","volume":"19","author":"G R","year":"2021","unstructured":"R G, S RP, Thomas A, Rengan AK. Doxorubicin loaded polyvinylpyrrolidone-copper sulfide nanoparticles enabling mucoadhesiveness and chemo-photothermal synergism for effective killing of breast cancer cells. Materialia. 2021;19:101195. https:\/\/doi.org\/10.1016\/j.mtla.2021.101195.","journal-title":"Materialia"},{"key":"2639_CR158","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/polym14050936","volume":"14","author":"NM AlSawaftah","year":"2022","unstructured":"AlSawaftah NM, Awad NS, Pitt WG, Husseini GA. pH-responsive nanocarriers in cancer therapy. Polymers (Basel). 2022;14:936. https:\/\/doi.org\/10.3390\/polym14050936.","journal-title":"Polymers (Basel)"},{"key":"2639_CR159","doi-asserted-by":"publisher","unstructured":"Chu S, Shi X, Tian Y, Gao F. pH-responsive polymer nanomaterials for tumor therapy. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.855019.","DOI":"10.3389\/fonc.2022.855019"},{"key":"2639_CR160","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/J.JCONREL.2021.08.003","volume":"337","author":"H Kaur","year":"2021","unstructured":"Kaur H, Kesharwani P. Advanced nanomedicine approaches applied for treatment of skin carcinoma. J Control Release. 2021;337:589\u2013611. https:\/\/doi.org\/10.1016\/J.JCONREL.2021.08.003.","journal-title":"J Control Release"},{"key":"2639_CR161","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3109\/1354750X.2012.715672","volume":"17","author":"MP Gamcsik","year":"2012","unstructured":"Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM. Glutathione levels in human tumors. Biomarkers. 2012;17:671\u201391. https:\/\/doi.org\/10.3109\/1354750X.2012.715672.","journal-title":"Biomarkers"},{"key":"2639_CR162","doi-asserted-by":"publisher","first-page":"269","DOI":"10.15171\/bi.2017.32","volume":"7","author":"M Fathi","year":"2017","unstructured":"Fathi M, Sahandi Zangabad P, Majidi S, Barar J, Erfan-Niya H, Omidi Y. Stimuli-responsive chitosan-based nanocarriers for cancer therapy. Bioimpacts. 2017;7:269\u201377. https:\/\/doi.org\/10.15171\/bi.2017.32.","journal-title":"Bioimpacts"},{"key":"2639_CR163","doi-asserted-by":"publisher","unstructured":"Mahmudi H, Adili-Aghdam MA, Shahpouri M, Jaymand M, Amoozgar Z, Jahanban-Esfahlan R. Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.1054029.","DOI":"10.3389\/fonc.2022.1054029"},{"key":"2639_CR164","doi-asserted-by":"publisher","unstructured":"Zhang S, Guo N, Wan G, Zhang T, Li C, Wang Y, Wang Y, Liu Y. PH and redox dual-responsive nanoparticles based on disulfide-containing poly(\u03b2-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer. J Nanobiotechnol. 2019;17. https:\/\/doi.org\/10.1186\/s12951-019-0540-9.","DOI":"10.1186\/s12951-019-0540-9"},{"key":"2639_CR165","doi-asserted-by":"publisher","first-page":"100265","DOI":"10.1016\/j.hybadv.2024.100265","volume":"6","author":"A Das","year":"2024","unstructured":"Das A, Ghosh S, Pramanik N. Chitosan biopolymer and its composites: processing, properties and applications- a comprehensive review. Hybrid Adv. 2024;6:100265. https:\/\/doi.org\/10.1016\/j.hybadv.2024.100265.","journal-title":"Hybrid Adv"},{"key":"2639_CR166","doi-asserted-by":"publisher","unstructured":"Fatima M, Sheikh A, Abourehab MAS, Kesharwani P. Advancements in polymeric nanocarriers to mediate targeted therapy against triple-negative breast cancer. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14112432.","DOI":"10.3390\/pharmaceutics14112432"},{"key":"2639_CR167","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/S12943-025-02435-2","volume":"24","author":"MS Khan","year":"2025","unstructured":"Khan MS, Rehman U, Alqahtani T, Al Shmrany H, Gupta G, Goh KW, et al. Advances in PLGA-based polymeric nanocarriers for colorectal cancer therapy: overcoming chemoresistance through controlled delivery strategies. Mol Cancer. 2025;24:288. https:\/\/doi.org\/10.1186\/S12943-025-02435-2.","journal-title":"Mol Cancer"},{"key":"2639_CR168","doi-asserted-by":"publisher","unstructured":"Alipour S, Aghamaali MR, Mahdavi A. Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2+ breast cancer. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-30507-2.","DOI":"10.1038\/s41598-025-30507-2"},{"key":"2639_CR169","doi-asserted-by":"publisher","unstructured":"Rani P, Jenifer H, Prabhu A, David D, Devanesan S, AlSalhi MS, Nicoletti M, Saravanan M. Enhancing anticancer efficacy: xovoltib-loaded chitosan-tripolyphosphate nanoparticles for targeted drug delivery against MCF-7 breast cancer cells. Mater Technol. 2024;39. https:\/\/doi.org\/10.1080\/10667857.2024.2381978.","DOI":"10.1080\/10667857.2024.2381978"},{"key":"2639_CR170","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/nano11061508","volume":"11","author":"I Ruseska","year":"2021","unstructured":"Ruseska I, Fresacher K, Petschacher C, Zimmer A. Use of protamine in nanopharmaceuticals\u2014a review. Nanomaterials. 2021;11:1508. https:\/\/doi.org\/10.3390\/nano11061508.","journal-title":"Nanomaterials"},{"key":"2639_CR171","doi-asserted-by":"publisher","first-page":"32956","DOI":"10.1039\/D2RA02005J","volume":"12","author":"MA Subhan","year":"2022","unstructured":"Subhan MA. Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics. RSC Adv. 2022;12:32956\u201378. https:\/\/doi.org\/10.1039\/D2RA02005J.","journal-title":"RSC Adv"},{"key":"2639_CR172","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1039\/D4RA08616C","volume":"15","author":"FM Duque","year":"2025","unstructured":"Duque FM, Falcone RD, Correa NM. Tailoring alginate nanoparticles: influence of reverse micelle templates on structure, size, and encapsulation properties. RSC Adv. 2025;15:7926\u201337. https:\/\/doi.org\/10.1039\/D4RA08616C.","journal-title":"RSC Adv"},{"key":"2639_CR173","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/cancers13051164","volume":"13","author":"F Andrade","year":"2021","unstructured":"Andrade F, Roca-Melendres MM, Dur\u00e1n-Lara EF, Rafael D, Schwartz S. Stimuli-responsive hydrogels for cancer treatment: the role of pH, light, ionic strength and magnetic field. Cancers (Basel). 2021;13:1164. https:\/\/doi.org\/10.3390\/cancers13051164.","journal-title":"Cancers (Basel)"},{"key":"2639_CR174","doi-asserted-by":"publisher","first-page":"12796","DOI":"10.1039\/D4RA00610K","volume":"14","author":"W Ma","year":"2024","unstructured":"Ma W, Zhao Q, Zhu S, Wang X, Zhang C, Ma D, et al. Construction of glutathione-responsive paclitaxel prodrug nanoparticles for image-guided targeted delivery and breast cancer therapy. RSC Adv. 2024;14:12796\u2013806. https:\/\/doi.org\/10.1039\/D4RA00610K.","journal-title":"RSC Adv"},{"key":"2639_CR175","doi-asserted-by":"publisher","first-page":"116527","DOI":"10.1016\/j.carbpol.2020.116527","volume":"245","author":"Z Chai","year":"2020","unstructured":"Chai Z, Teng C, Yang L, Ren L, Yuan Z, Xu S, et al. Doxorubicin delivered by redox-responsive Hyaluronic Acid-Ibuprofen prodrug micelles for treatment of metastatic breast cancer. Carbohydr Polym. 2020;245:116527. https:\/\/doi.org\/10.1016\/j.carbpol.2020.116527.","journal-title":"Carbohydr Polym"},{"key":"2639_CR176","doi-asserted-by":"publisher","first-page":"119833","DOI":"10.1016\/j.carbpol.2022.119833","volume":"294","author":"A Sood","year":"2022","unstructured":"Sood A, Gupta A, Bharadwaj R, Ranganath P, Silverman N, Agrawal G. Biodegradable disulfide crosslinked chitosan\/stearic acid nanoparticles for dual drug delivery for colorectal cancer. Carbohydr Polym. 2022;294:119833. https:\/\/doi.org\/10.1016\/j.carbpol.2022.119833.","journal-title":"Carbohydr Polym"},{"key":"2639_CR177","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.3390\/ma15155290","volume":"15","author":"Z Ren","year":"2022","unstructured":"Ren Z, Liao T, Li C, Kuang Y. Drug delivery systems with a \u201ctumor-triggered\u201d targeting or intracellular drug release property based on dePEGylation. Materials Basel. 2022;15:5290. https:\/\/doi.org\/10.3390\/ma15155290.","journal-title":"Materials Basel"},{"key":"2639_CR178","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2147\/IJN.S293427","volume":"16","author":"R Jia","year":"2021","unstructured":"Jia R, Teng L, Gao L, Su T, Fu L, Qiu Z, et al. Advances in multiple stimuli-responsive drug-delivery systems for cancer therapy. Int J Nanomedicine. 2021;16:1525\u201351. https:\/\/doi.org\/10.2147\/IJN.S293427.","journal-title":"Int J Nanomedicine"},{"key":"2639_CR179","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2174\/0115672018340056240924183806","volume":"22","author":"S Ehsanimehr","year":"2025","unstructured":"Ehsanimehr S, Badr K, Dehaen W, Irannejad VS, Moghadam PN. Multi-stimuli-responsive biocompatible magnetic nanocarrier as drug delivery system to MCF-7 breast cancer cells. Curr Drug Deliv. 2025;22:1201\u201316. https:\/\/doi.org\/10.2174\/0115672018340056240924183806.","journal-title":"Curr Drug Deliv"},{"key":"2639_CR180","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.apsb.2020.08.009","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Zou J, Zhang K, Zhu J, Zhang Y, Zhu Z, et al. Photothermal\/matrix metalloproteinase-2 dual-responsive gelatin nanoparticles for breast cancer treatment. Acta Pharm Sin B. 2021;11:271\u201382. https:\/\/doi.org\/10.1016\/j.apsb.2020.08.009.","journal-title":"Acta Pharm Sin B"},{"key":"2639_CR181","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/gels2010006","volume":"2","author":"K Rao","year":"2016","unstructured":"Rao K, Rao K, Ha C-S. Stimuli responsive poly(vinyl caprolactam) gels for biomedical applications. Gels. 2016;2:6. https:\/\/doi.org\/10.3390\/gels2010006.","journal-title":"Gels"},{"key":"2639_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-019-0529-4","volume":"17","author":"S Niu","year":"2019","unstructured":"Niu S, Williams GR, Wu J, Wu J, Zhang X, Chen X, et al. A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy. J Nanobiotechnology. 2019;17:1\u201318. https:\/\/doi.org\/10.1186\/s12951-019-0529-4.","journal-title":"J Nanobiotechnology"},{"key":"2639_CR183","doi-asserted-by":"publisher","first-page":"42135","DOI":"10.1021\/acsomega.5c04565","volume":"10","author":"V Colaco","year":"2025","unstructured":"Colaco V, Datta D, Kudarha R, Singh AK, Dhas N. Microneedles as gateways: smart nanoparticle delivery for enhanced breast cancer treatment. ACS Omega. 2025;10:42135\u201350. https:\/\/doi.org\/10.1021\/acsomega.5c04565.","journal-title":"ACS Omega"},{"key":"2639_CR184","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.62347\/VZAW2270","volume":"16","author":"Z Yu","year":"2024","unstructured":"Yu Z. Reversal of postoperative breast cancer metastasis by the use of embedded hydrogel. Am J Transl Res. 2024;16:6991\u20137015. https:\/\/doi.org\/10.62347\/VZAW2270.","journal-title":"Am J Transl Res"},{"key":"2639_CR185","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/pharmaceutics14030661","volume":"14","author":"AAH Abdellatif","year":"2022","unstructured":"Abdellatif AAH, Mohammed AM, Saleem I, Alsharidah M, Al Rugaie O, Ahmed F, et al. Smart injectable chitosan hydrogels loaded with 5-fluorouracil for the treatment of breast cancer. Pharmaceutics. 2022;14:661. https:\/\/doi.org\/10.3390\/pharmaceutics14030661.","journal-title":"Pharmaceutics"},{"key":"2639_CR186","doi-asserted-by":"publisher","first-page":"148453","DOI":"10.1016\/j.ijbiomac.2025.148453","volume":"331","author":"D Ailincai","year":"2025","unstructured":"Ailincai D, Bercea M, Rosca I, Sandu IA, Marin L. Chitosan based hydrogels as temporary implants for breast cancer postsurgical treatment and site-infections prophylaxis. Int J Biol Macromol. 2025;331:148453. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148453.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR187","doi-asserted-by":"publisher","first-page":"138930","DOI":"10.1016\/j.ijbiomac.2024.138930","volume":"290","author":"X Hou","year":"2025","unstructured":"Hou X, Guan Y, Lu Y, Wang Y, Xu S, Zhu H, et al. Chitosan-based thermosensitive injectable hydrogel with hemostatic and antibacterial activity for preventing breast cancer postoperative recurrence and metastasis via chemo-photothermal therapy. Int J Biol Macromol. 2025;290:138930. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.138930.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR188","doi-asserted-by":"publisher","first-page":"145947","DOI":"10.1016\/j.ijbiomac.2025.145947","volume":"320","author":"GP Sahoo","year":"2025","unstructured":"Sahoo GP, Rai VK, Pradhan D, Halder J, Rajwar TK, Mahanty R, et al. Advances in chitosan-based nanofiber for breast cancer treatment: a review. Int J Biol Macromol. 2025;320:145947. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145947.","journal-title":"Int J Biol Macromol"},{"key":"2639_CR189","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.2147\/IJN.S329855","volume":"16","author":"Z Ye","year":"2021","unstructured":"Ye Z, Liang L, Lu H, Shen Y, Zhou W, Li Y. Nanotechnology-employed bacteria-based delivery strategy for enhanced anticancer therapy. Int J Nanomedicine. 2021;16:8069\u201386. https:\/\/doi.org\/10.2147\/IJN.S329855.","journal-title":"Int J Nanomedicine"},{"key":"2639_CR190","doi-asserted-by":"publisher","unstructured":"Yan S, Gan Y, Xu H, Piao H. Bacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy. Front Bioeng Biotechnol. 2025;12. https:\/\/doi.org\/10.3389\/fbioe.2024.1526612.","DOI":"10.3389\/fbioe.2024.1526612"},{"key":"2639_CR191","doi-asserted-by":"publisher","unstructured":"Rakhshani A, Maghsoudian S, Mousavi N, Yousefi M. International Journal of Biological Macromolecules Polyethylene oxide-chitosan-doxorubicin \/ polycaprolactone-chitosan-curcumin pH-sensitive core \/ shell nanofibrous mats for the treatment of breast cancer\u202f: Fabrication , characterization and in vitro and. Int J Biol Macromol. 2025;305:141191. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.141191.","DOI":"10.1016\/j.ijbiomac.2025.141191"},{"key":"2639_CR192","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1021\/acs.molpharmaceut.6b00776","volume":"13","author":"AM Butt","year":"2016","unstructured":"Butt AM, Amin MCIM, Katas H, Abdul Murad NA, Jamal R, Kesharwani P. Doxorubicin and siRNA codelivery via chitosan-coated pH-responsive mixed micellar polyplexes for enhanced cancer therapy in multidrug-resistant tumors. Mol Pharm. 2016;13:4179\u201390. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00776.","journal-title":"Mol Pharm"},{"key":"2639_CR193","doi-asserted-by":"publisher","unstructured":"Sun L, Li Z, Lan J, Wu Y, Zhang T, Ding Y. Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy. Front Pharmacol. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1389922.","DOI":"10.3389\/fphar.2024.1389922"},{"key":"2639_CR194","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.apsb.2015.03.001","volume":"5","author":"L Kang","year":"2015","unstructured":"Kang L, Gao Z, Huang W, Jin M, Wang Q. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B. 2015;5:169\u201375. https:\/\/doi.org\/10.1016\/j.apsb.2015.03.001.","journal-title":"Acta Pharm Sin B"},{"key":"2639_CR195","doi-asserted-by":"publisher","first-page":"djv212","DOI":"10.1093\/jnci\/djv212","volume":"107","author":"SRD Johnston","year":"2015","unstructured":"Johnston SRD. Enhancing endocrine therapy for hormone receptor\u2013positive advanced breast cancer: cotargeting signaling pathways. J Natl Cancer Inst. 2015;107:djv212. https:\/\/doi.org\/10.1093\/jnci\/djv212.","journal-title":"J Natl Cancer Inst"},{"key":"2639_CR196","doi-asserted-by":"publisher","unstructured":"Lunawat AK, Thakur S, Das Kurmi B, Das Gupta G, Patel P, Raikwar S. Revolutionizing cancer treatment: The role of chitosan nanoparticles in therapeutic advancements. J. Drug Deliv Sci Technol. 2024;96. https:\/\/doi.org\/10.1016\/j.jddst.2024.105661.","DOI":"10.1016\/j.jddst.2024.105661"},{"key":"2639_CR197","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1158\/1078-0432.CCR-07-5023","volume":"15","author":"E White","year":"2009","unstructured":"White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 2009;15:5308\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5023.","journal-title":"Clin Cancer Res"},{"key":"2639_CR198","doi-asserted-by":"publisher","unstructured":"Khan MS, Alqahtani T, Al Shmrany H, Gupta G, Goh KW, Sahebkar A, Kesharwani P. Enhanced permeability and retention (EPR) effect: Advances in nanomedicine for improved tumor targeting. Biomater Adv. 2026;181. https:\/\/doi.org\/10.1016\/j.bioadv.2025.214636.","DOI":"10.1016\/j.bioadv.2025.214636"},{"key":"2639_CR199","doi-asserted-by":"publisher","first-page":"34313","DOI":"10.1038\/s41598-025-20184-6","volume":"15","author":"AM Radwan","year":"2025","unstructured":"Radwan AM, El-Atrash A, Elkholy M, Nawar NF, Tousson E, Ghoneim AI. In vivo antitumor activity of doxorubicin loaded on chitosan functionalized Pb2Mn2Fe12O22 magnetic nanoparticles. Sci Rep. 2025;15:34313. https:\/\/doi.org\/10.1038\/s41598-025-20184-6.","journal-title":"Sci Rep"},{"key":"2639_CR200","doi-asserted-by":"publisher","first-page":"112623","DOI":"10.1016\/j.msec.2021.112623","volume":"133","author":"NA D\u2019Angelo","year":"2022","unstructured":"D\u2019Angelo NA, Noronha MA, C\u00e2mara MCC, Kurnik IS, Feng C, Araujo VHS, et al. Doxorubicin nanoformulations on therapy against cancer: an overview from the last 10 years. Biomater Adv. 2022;133:112623. https:\/\/doi.org\/10.1016\/j.msec.2021.112623.","journal-title":"Biomater Adv"},{"key":"2639_CR201","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.colcom.2025.100861","volume":"69","author":"MA Khorasani","year":"2025","unstructured":"Khorasani MA, Naghib SM, Jafari T, Takdehghan G. Recent advances in engineering chitosan-based nanoplatforms in biotherapeutic multi-delivery for multi-targeted disease treatments: promises and outlooks. Colloid Interface Sci Commun. 2025;69:100861. https:\/\/doi.org\/10.1016\/j.colcom.2025.100861.","journal-title":"Colloid Interface Sci Commun"},{"key":"2639_CR202","doi-asserted-by":"publisher","first-page":"102358","DOI":"10.1016\/j.mtbio.2025.102358","volume":"35","author":"MT El-Saadony","year":"2025","unstructured":"El-Saadony MT, Saad AM, Sitohy M, Alkafaas SS, Dladla M, Ghosh S, et al. Chitosan nanoparticles: green synthesis, biological activities, and sustainable frontiers in targeted drug delivery and cancer nanomedicine \u2013 a comprehensive review. Mater Today Bio. 2025;35:102358. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102358.","journal-title":"Mater Today Bio"},{"key":"2639_CR203","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.carpta.2025.100797","volume":"10","author":"M Ghattas","year":"2025","unstructured":"Ghattas M, Chevrier A, Wang D, Alameh M-G, Lavertu M. Reducing endotoxin contamination in chitosan: an optimized purification method for biomedical applications. Carbohydr Polym Technol Appl. 2025;10:100797. https:\/\/doi.org\/10.1016\/j.carpta.2025.100797.","journal-title":"Carbohydr Polym Technol Appl"},{"key":"2639_CR204","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/cancers11071026","volume":"11","author":"DE Korenchan","year":"2019","unstructured":"Korenchan DE, Flavell RR. Spatiotemporal pH heterogeneity as a promoter of cancer progression and therapeutic resistance. Cancers (Basel). 2019;11:1026. https:\/\/doi.org\/10.3390\/cancers11071026.","journal-title":"Cancers (Basel)"},{"key":"2639_CR205","doi-asserted-by":"publisher","unstructured":"Ahmad S, Idris RAM, Wan Hanaffi WN, Perumal K, Boer JC, Plebanski M, Jaafar J, Lim JK, Mohamud R. Cancer Nanomedicine and Immune System\u2014Interactions and Challenges. Front Nanotechnol. 2021;3. https:\/\/doi.org\/10.3389\/fnano.2021.681305.","DOI":"10.3389\/fnano.2021.681305"},{"key":"2639_CR206","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.bioactmat.2026.01.036","volume":"60","author":"D Esmaeilpour","year":"2026","unstructured":"Esmaeilpour D, Hamblin MR, Cheng J, Khosravi A, Liu J, Zarepour A, et al. Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics. Bioact Mater. 2026;60:425. https:\/\/doi.org\/10.1016\/j.bioactmat.2026.01.036.","journal-title":"Bioact Mater"},{"key":"2639_CR207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJN.S568254","volume":"21","author":"V Gupta","year":"2026","unstructured":"Gupta V, Kumar D, Gupta S, Tanwar R, Jaiswal NK, Islam MM, et al. Nanotechnology-driven cancer therapies for precision oncology: advances and clinical outlook. Int J Nanomedicine. 2026;21:1\u201333. https:\/\/doi.org\/10.2147\/IJN.S568254.","journal-title":"Int J Nanomedicine"},{"issue":"13","key":"2639_CR208","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1038\/s41598-023-30911-6","volume":"2023","author":"NEA El-Naggar","year":"2023","unstructured":"El-Naggar NEA, Dalal SR, Zweil AM, Eltarahony M. Artificial intelligence-based optimization for chitosan nanoparticles biosynthesis, characterization and in-vitro assessment of its anti-biofilm potentiality. Sci Reports. 2023;2023(13):4401. https:\/\/doi.org\/10.1038\/s41598-023-30911-6.","journal-title":"Sci Reports."},{"key":"2639_CR209","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1039\/d4dd00104d","volume":"3","author":"A Ortiz-Perez","year":"2024","unstructured":"Ortiz-Perez A, van Tilborg D, van der Meel R, Grisoni F, Albertazzi L. Machine learning-guided high throughput nanoparticle design. Digit Discov. 2024;3:1280\u201391. https:\/\/doi.org\/10.1039\/d4dd00104d.","journal-title":"Digit Discov"},{"key":"2639_CR210","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1080\/03639045.2025.2569573","volume":"51","author":"A Rastegari","year":"2025","unstructured":"Rastegari A, Faghihi H, Mobinikhaledi M. Prediction drug release profile from chitosan nanoparticles: integration of experimental data and machine learning models. Drug Dev Ind Pharm. 2025;51:1819\u201327. https:\/\/doi.org\/10.1080\/03639045.2025.2569573.","journal-title":"Drug Dev Ind Pharm"},{"key":"2639_CR211","doi-asserted-by":"publisher","first-page":"1546010","DOI":"10.3389\/fphar.2025.1546010","volume":"16","author":"EA Elmorsy","year":"2025","unstructured":"Elmorsy EA, Saber S, Al-Majdoub ZM, Hamad RS, Abdel-Reheim MA, Ramadan A, et al. Innovative pH-responsive alginate-coated rosuvastatin-loaded chitosan nanoparticles: a targeted approach to inhibiting HMGB1-activated RAGE\/TLR4-NF\u03baB signaling in colonic inflammation in rats. Front Pharmacol. 2025;16:1546010. https:\/\/doi.org\/10.3389\/fphar.2025.1546010.","journal-title":"Front Pharmacol"},{"key":"2639_CR212","doi-asserted-by":"publisher","first-page":"e44837","DOI":"10.7759\/cureus.44837","volume":"15","author":"M Alhaja","year":"2023","unstructured":"Alhaja M, Chen S, Chin AC, Schulte B, Legasto CS. Cardiac safety of pegylated liposomal doxorubicin after conventional doxorubicin exposure in patients with sarcoma and breast cancer. Cureus. 2023;15:e44837. https:\/\/doi.org\/10.7759\/cureus.44837.","journal-title":"Cureus"},{"key":"2639_CR213","doi-asserted-by":"publisher","first-page":"451","DOI":"10.7150\/ntno.75045","volume":"6","author":"MR Islam","year":"2022","unstructured":"Islam MR, Patel J, Back PI, Shmeeda H, Adamsky K, Yang H, et al. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model. Nanotheranostics. 2022;6:451\u201364. https:\/\/doi.org\/10.7150\/ntno.75045.","journal-title":"Nanotheranostics"},{"key":"2639_CR214","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1211\/jpp.61.02.0001","volume":"61","author":"ML Tan","year":"2009","unstructured":"Tan ML, Choong PFM, Dass CR. Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol. 2009;61:131\u201342. https:\/\/doi.org\/10.1211\/jpp.61.02.0001.","journal-title":"J Pharm Pharmacol"},{"key":"2639_CR215","doi-asserted-by":"publisher","first-page":"111708","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. https:\/\/doi.org\/10.1016\/j.biopha.2021.111708.","journal-title":"Biomed Pharmacother"},{"key":"2639_CR216","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1023\/A:1008365716693","volume":"11","author":"T Safra","year":"2000","unstructured":"Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2. Ann Oncol. 2000;11:1029\u201334. https:\/\/doi.org\/10.1023\/A:1008365716693.","journal-title":"Ann Oncol"},{"key":"2639_CR217","doi-asserted-by":"publisher","first-page":"605","DOI":"10.21037\/atm-22-1935","volume":"10","author":"Y Sun","year":"2022","unstructured":"Sun Y, Ping Y, Miao S, Li Z, Pan C, Shen S, et al. Development of a multivariable clinical prediction model for liposomal doxorubicin-induced cardiotoxicity in adult breast cancer patients: a retrospective multicenter study. Ann Transl Med. 2022;10:605\u2013605. https:\/\/doi.org\/10.21037\/atm-22-1935.","journal-title":"Ann Transl Med"},{"key":"2639_CR218","doi-asserted-by":"publisher","unstructured":"Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a. Ann Oncol. 2003;14:833-842. https:\/\/doi.org\/10.1093\/annonc\/mdg260.","DOI":"10.1093\/annonc\/mdg260"},{"key":"2639_CR219","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/iwj.13911","volume":"20","author":"J Hu","year":"2023","unstructured":"Hu J, Lin Y, Cui C, Zhang F, Su T, Guo K, et al. Clinical efficacy of wet dressing combined with chitosan wound dressing in the treatment of deep second-degree burn wounds: a prospective, randomised, single-blind, positive control clinical trial. Int Wound J. 2023;20:699\u2013705. https:\/\/doi.org\/10.1111\/iwj.13911.","journal-title":"Int Wound J"},{"key":"2639_CR220","doi-asserted-by":"publisher","unstructured":"Rajinikanth B S, Rajkumar DSR, Vijayaragavan, Chitosan-Based Biomaterial in Wound Healing: A Review. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.55193.","DOI":"10.7759\/cureus.55193"},{"key":"2639_CR221","doi-asserted-by":"publisher","first-page":"BCBCR.S9454","DOI":"10.4137\/BCBCR.S9454","volume":"8","author":"MM Rampurwala","year":"2014","unstructured":"Rampurwala MM, Rocque GB, Burkard ME. Update on adjuvant chemotherapy for early breast cancer. Breast Cancer Basic Clin Res. 2014;8:BCBCR.S9454. https:\/\/doi.org\/10.4137\/BCBCR.S9454.","journal-title":"Breast Cancer Basic Clin Res"},{"key":"2639_CR222","doi-asserted-by":"publisher","first-page":"106007","DOI":"10.1016\/j.jddst.2024.106007","volume":"100","author":"A Aravindan","year":"2024","unstructured":"Aravindan A, Gupta A, Moorkoth S, Dhas N. Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: the state-of-the-art review. J Drug Deliv Sci Technol. 2024;100:106007. https:\/\/doi.org\/10.1016\/j.jddst.2024.106007.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2639_CR223","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.colcom.2025.100861","volume":"69","author":"MA Khorasani","year":"2025","unstructured":"Khorasani MA, Naghib SM, Jafari T, Takdehghan G. Recent advances in engineering chitosan-based nanoplatforms in biotherapeutic multi-delivery for multi-targeted disease treatments: promises and outlooks. Colloid Interface Sci Commun. 2025;69:100861. https:\/\/doi.org\/10.1016\/j.colcom.2025.100861.","journal-title":"Colloid Interface Sci Commun"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02639-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:06:21Z","timestamp":1778151981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02639-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":223,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2639"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02639-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}